Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.

Dwyer CJ, Knochelmann HM, Smith AS, Wyatt MM, Rangel Rivera GO, Arhontoulis DC, Bartee E, Li Z, Rubinstein MP, Paulos CM.

Front Immunol. 2019 Feb 20;10:263. doi: 10.3389/fimmu.2019.00263. eCollection 2019. Review.

2.

Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.

Johnson CB, May BR, Riesenberg BP, Suriano S, Mehrotra S, Garrett-Mayer E, Salem ML, Jeng EK, Wong HC, Paulos CM, Wrangle JM, Cole DJ, Rubinstein MP.

Cancer Res. 2018 Jun 1;78(11):3067-3074. doi: 10.1158/0008-5472.CAN-17-2153. Epub 2018 Apr 10.

PMID:
29636345
3.

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.

Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.

4.

IL-2 and Beyond in Cancer Immunotherapy.

Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP.

J Interferon Cytokine Res. 2018 Feb;38(2):45-68. doi: 10.1089/jir.2017.0101.

5.

The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.

Riley JM, Cross AW, Paulos CM, Rubinstein MP, Wrangle J, Camp ER.

Cancer. 2018 Apr 15;124(8):1650-1659. doi: 10.1002/cncr.31214. Epub 2018 Jan 9. Review.

PMID:
29315503
6.

Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, Camp ER, Rockey DC, Schell TD, Staveley-O'Carroll KF.

Oncoimmunology. 2017 Sep 21;7(1):e1372079. doi: 10.1080/2162402X.2017.1372079. eCollection 2017.

7.

Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.

Wrangle J, Paulos CM, Smith TW Jr, Nishimura MI, Rubinstein MP.

Mol Ther. 2017 Sep 6;25(9):1995-1996. doi: 10.1016/j.ymthe.2017.08.002. Epub 2017 Aug 19. No abstract available.

8.

Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.

Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M, Bearden DW, Yang Y, Liu B, Li Z.

Sci Immunol. 2017 May 5;2(11). pii: eaai7911. doi: 10.1126/sciimmunol.aai7911.

9.

β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.

Majchrzak K, Nelson MH, Bowers JS, Bailey SR, Wyatt MM, Wrangle JM, Rubinstein MP, Varela JC, Li Z, Himes RA, Chan SS, Paulos CM.

JCI Insight. 2017 Apr 20;2(8). pii: 90547. doi: 10.1172/jci.insight.90547. eCollection 2017 Apr 20.

10.

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.

Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, Paulos CM, Salazar AM, Nishimura MI, Rubinstein MP, Li Z, Cole DJ.

J Hematol Oncol. 2017 Apr 7;10(1):82. doi: 10.1186/s13045-017-0459-2.

11.

Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.

Neitzke DJ, Bowers JS, Andrijauskaite K, O'Connell NS, Garrett-Mayer E, Wrangle J, Li Z, Paulos CM, Cole DJ, Rubinstein MP.

Cancer Immunol Immunother. 2017 Jun;66(6):737-751. doi: 10.1007/s00262-017-1965-3. Epub 2017 Mar 9.

12.

A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.

Liu B, Kong L, Han K, Hong H, Marcus WD, Chen X, Jeng EK, Alter S, Zhu X, Rubinstein MP, Shi S, Rhode PR, Cai W, Wong HC.

J Biol Chem. 2016 Nov 11;291(46):23869-23881. Epub 2016 Sep 20.

13.

Molecular Programming of Tumor-Infiltrating CD8+ T Cells and IL15 Resistance.

Doedens AL, Rubinstein MP, Gross ET, Best JA, Craig DH, Baker MK, Cole DJ, Bui JD, Goldrath AW.

Cancer Immunol Res. 2016 Sep 2;4(9):799-811. doi: 10.1158/2326-6066.CIR-15-0178. Epub 2016 Aug 2.

14.

Harnessing the IL-7/IL-7Rα axis to improve tumor immunotherapy.

Johnson CB, Wrangle J, Mehrotra S, Li Z, Paulos CM, Cole DJ, Surh CD, Rubinstein MP.

Oncoimmunology. 2016 Jan 19;5(5):e1122865. doi: 10.1080/2162402X.2015.1122865. eCollection 2016 May.

15.

Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M, Al-Hommrani M, Andrijauskaite K, Moxley K, Janakiraman H, Scheffel MJ, Helke K, Armenson K, Palanisamy V, Rubinstein MP, Mayer EG, Cole DJ, Paulos CM, Christina-Voelkel-Johnson, Nishimura MI, Mehrotra S.

Cancer Res. 2016 Sep 15;76(18):5229-5240. doi: 10.1158/0008-5472.CAN-15-1798. Epub 2016 Jul 27.

16.

Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.

Majchrzak K, Nelson MH, Bailey SR, Bowers JS, Yu XZ, Rubinstein MP, Himes RA, Paulos CM.

Cancer Immunol Immunother. 2016 Mar;65(3):247-59. doi: 10.1007/s00262-016-1797-6. Epub 2016 Jan 29. Review.

17.

IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.

Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, Paulos CM, Doedens AL, Goldrath AW, Li Z, Cole DJ, Rubinstein MP.

Sci Transl Med. 2015 Oct 28;7(311):311ra170. doi: 10.1126/scitranslmed.aac8155.

18.

Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.

Johnson CB, Riesenberg BP, May BR, Gilreath SC, Li G, Staveley-O'Carroll KF, Garrett-Mayer E, Mehrotra S, Cole DJ, Rubinstein MP.

Cancer Immunol Res. 2015 Dec;3(12):1364-74. doi: 10.1158/2326-6066.CIR-15-0087-T. Epub 2015 Aug 21.

19.

IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.

Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP.

Cancer Gene Ther. 2015 Jul;22(7):360-7. doi: 10.1038/cgt.2015.28. Epub 2015 Jul 17.

20.

Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.

Bowers JS, Nelson MH, Kundimi S, Bailey SR, Huff LW, Schwartz KM, Cole DJ, Rubinstein MP, Paulos CM.

Clin Cancer Res. 2015 Jun 1;21(11):2546-57. doi: 10.1158/1078-0432.CCR-14-2294. Epub 2015 Apr 22.

21.

Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.

Rubinstein MP, Su EW, Suriano S, Cloud CA, Andrijauskaite K, Kesarwani P, Schwartz KM, Williams KM, Johnson CB, Li M, Scurti GM, Salem ML, Paulos CM, Garrett-Mayer E, Mehrotra S, Cole DJ.

Cancer Immunol Immunother. 2015 May;64(5):539-49. doi: 10.1007/s00262-015-1655-y. Epub 2015 Feb 13.

22.

The inducible costimulator augments Tc17 cell responses to self and tumor tissue.

Nelson MH, Kundimi S, Bowers JS, Rogers CE, Huff LW, Schwartz KM, Thyagarajan K, Little EC, Mehrotra S, Cole DJ, Rubinstein MP, Paulos CM.

J Immunol. 2015 Feb 15;194(4):1737-47. doi: 10.4049/jimmunol.1401082. Epub 2015 Jan 9.

23.

Cancer immunotherapy: are we there yet?

Li Z, Chen L, Rubinstein MP.

Exp Hematol Oncol. 2013 Dec 10;2(1):33. doi: 10.1186/2162-3619-2-33.

24.

G-CSF/anti-G-CSF antibody complexes drive the potent recovery and expansion of CD11b+Gr-1+ myeloid cells without compromising CD8+ T cell immune responses.

Rubinstein MP, Salem ML, Doedens AL, Moore CJ, Chiuzan C, Rivell GL, Cole DJ, Goldrath AW.

J Hematol Oncol. 2013 Oct 1;6:75. doi: 10.1186/1756-8722-6-75.

25.

Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.

Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR, Wong HC.

Cancer Res. 2013 May 15;73(10):3075-86. doi: 10.1158/0008-5472.CAN-12-2357. Epub 2013 May 3.

26.

Soluble IL-15/IL-15Rα complexes in human serum.

Cole DJ, Rubinstein MP.

Blood. 2012 Jul 5;120(1):1-2. doi: 10.1182/blood-2012-04-425306.

27.

Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ.

J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8. doi: 10.1016/j.jamcollsurg.2011.12.034. Epub 2012 Feb 22.

28.

Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes.

Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ.

Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21647-52. doi: 10.1073/pnas.1012128107. Epub 2010 Nov 22.

29.

Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression.

Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS.

Cancer Res. 2010 Oct 1;70(19):7465-75. doi: 10.1158/0008-5472.CAN-10-1439. Epub 2010 Sep 14.

30.

Surviving the crash: transitioning from effector to memory CD8+ T cell.

D'Cruz LM, Rubinstein MP, Goldrath AW.

Semin Immunol. 2009 Apr;21(2):92-8. doi: 10.1016/j.smim.2009.02.002. Epub 2009 Mar 6. Review.

31.

Loss of T cell-mediated antitumor immunity after construct-specific downregulation of retrovirally encoded T-cell receptor expression in vivo.

Rubinstein MP, Salem ML, Kadima AN, Nguyen CL, Gillanders WE, Nishimura MI, Cole DJ.

Cancer Gene Ther. 2009 Feb;16(2):171-83. doi: 10.1038/cgt.2008.63. Epub 2008 Aug 8.

32.

IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response.

Rubinstein MP, Lind NA, Purton JF, Filippou P, Best JA, McGhee PA, Surh CD, Goldrath AW.

Blood. 2008 Nov 1;112(9):3704-12. doi: 10.1182/blood-2008-06-160945. Epub 2008 Aug 8.

33.

Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells.

Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ.

Cancer Res. 2008 Apr 15;68(8):2972-83. doi: 10.1158/0008-5472.CAN-08-0045.

34.
35.

An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2.

Cho JH, Boyman O, Kim HO, Hahm B, Rubinstein MP, Ramsey C, Kim DM, Surh CD, Sprent J.

J Exp Med. 2007 Aug 6;204(8):1787-801. Epub 2007 Jul 30.

36.

Antiviral CD4+ memory T cells are IL-15 dependent.

Purton JF, Tan JT, Rubinstein MP, Kim DM, Sprent J, Surh CD.

J Exp Med. 2007 Apr 16;204(4):951-61. Epub 2007 Apr 9.

38.

Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity.

Salem ML, Gillanders WE, Kadima AN, El-Naggar S, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ.

J Interferon Cytokine Res. 2006 Sep;26(9):593-608. Review.

PMID:
16978064
39.

Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}.

Rubinstein MP, Kovar M, Purton JF, Cho JH, Boyman O, Surh CD, Sprent J.

Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9166-71. Epub 2006 Jun 6.

40.

Selective stimulation of T cell subsets with antibody-cytokine immune complexes.

Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J.

Science. 2006 Mar 31;311(5769):1924-7. Epub 2006 Feb 16.

41.

Management options for the flat corneal graft.

Lagnado R, Rubinstein MP, Maharajan S, Dua HS.

Cont Lens Anterior Eye. 2004 Mar;27(1):27-31.

PMID:
16303524
42.

The use of hybrid lenses in management of the irregular cornea.

Rubinstein MP, Sud S.

Cont Lens Anterior Eye. 1999;22(3):87-90.

PMID:
16303411
43.

Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine.

Salem ML, Kadima AN, Zhou Y, Nguyen CL, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE.

J Immunol. 2004 May 1;172(9):5159-67.

44.

Applications of contact lens devices in the management of corneal disease.

Rubinstein MP.

Eye (Lond). 2003 Nov;17(8):872-6. Review.

PMID:
14631391
45.

Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2).

Nguyen CL, Salem ML, Rubinstein MP, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE.

Vaccine. 2003 Jun 2;21(19-20):2318-28.

PMID:
12744862
46.

CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.

Roszkowski JJ, Yu DC, Rubinstein MP, McKee MD, Cole DJ, Nishimura MI.

J Immunol. 2003 Mar 1;170(5):2582-9.

47.

Transfer of TCR genes into mature T cells is accompanied by the maintenance of parental T cell avidity.

Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Nishimura MI, Cole DJ.

J Immunol. 2003 Feb 1;170(3):1209-17.

48.

Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.

Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ.

J Immunol. 2002 Nov 1;169(9):4928-35.

49.

Distance telescopes: a survey of user success.

Lowe JB, Rubinstein MP.

Optom Vis Sci. 2000 May;77(5):260-9.

PMID:
10831216
50.

Therapeutic contact lenses and eyedrops--is there a problem?

Rubinstein MP, Evans JE.

Cont Lens Anterior Eye. 1997;20(1):9-11.

PMID:
16303342

Supplemental Content

Loading ...
Support Center